chemie.pr-Pressemitteilungen und Pressemeldungen vom 31.08.2008 | PresseEcho.de
ARB Trial Against Placebo Shows MICARDIS(R) (Telmisartan) Reduces of Cardiovascular Death, Heart Attack and Stroke in ACE-Intolerant High-Risk Patients(1)
First Landmark ARB Trial Against Placebo Shows MICARDIS(R) (Telmisartan) Reduces the Risk of Cardiovascular Death, Heart Attack and Stroke in ACE-Intolerant High-Risk Patients(1)
31.08.2008 12:40:05
Boehringer Ingelheim: Munich, Germany (ots/PRNewswire) - - TRANSCEND(R), Parallel Trial to ONTARGET(R), Confirms Long-Term Protective Benefits and Excellent Tolerability Profile of Telmisartan 80mg(1) on Top of Current Best Standard of Care MUNICH, ...
Lesen Sie hier weiter... |
Drucken |
PDF
Ähnliche Artikel
- Telmisartan (MICARDIS(R)) as Effective as Ramipril But With Better Long-Term Tolerability in High-Risk Cardiovascular Asian Patients
- Atrial Fibrillation Found to be Common in Patients With Atherothrombosis, Increases Risk of Cardiovascular Death, Heart Attack and Stroke
- SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease
- New Survey Among European Cardiologists Points to a Gap in Cardiovascular Disease Management
- Unique New Initiative by World-Recognized Specialists in Heart Disease and Diabetes to Reduce Residual Vascular Risk Launched Today
- Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation or Death in Patients With Atrial Fibrillation
- American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
- MICARDIS(R)- Based Regimens Help More Patients Achieve Their Blood Pressure Goals
- CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
- Fenofibrate Reduces the Risk of Amputations in Patients With Type 2 Diabetes
ots.at: das APA-OTS-Portal für multimediale Presseaussendungen
ARB Trial Against Placebo Shows MICARDIS(R) (Telmisartan) Reduces of Cardiovascular Death, Heart Attack and Stroke in ACE-Intolerant High-Risk Patients(1)
Bankkaufmann - News
ARB Trial Against Placebo Shows MICARDIS(R) (Telmisartan) Reduces of Cardiovascular Death, Heart Attack and Stroke in ACE-Intolerant High-Risk Patients(1)
Presseportal: Boehringer Ingelheim - Medieneinladung: Sind Sie auf das ...
ARB Trial Against Placebo Shows MICARDIS(R) (Telmisartan) Risk of Cardiovascular Death, Heart Attack and Stroke in ACE-Intolerant High-Risk Patients(1)
Presseportal.de - Boehringer Ingelheim
ARB Trial Against Placebo Shows MICARDIS(R) (Telmisartan) Reduces of Cardiovascular Death, Heart Attack and Stroke in ACE-Intolerant High-Risk Patients(1)